In response to Dr Shabih Manzar regarding ACTH and cortisol response to critical illness in term and late-preterm neonates In response to Dr Manzar's question of treating with adrenocorticotropin (ACTH) or corticotropin-releasing hormone (CRH) rather than hydrocortisone, there are currently no therapeutic indications in relative adrenal insufficiency for use of CRH or ACTH expect for diagnostic testing. 1 This route of treatment has not been studied for this problem because CRH and ACTH administration may result in a large variation of cortisol levels that are unregulated and would be difficult to predict as opposed to giving the end product, cortisol directly.
Regarding mechanisms for adrenal insufficiency, the ill newborn infant may be at risk for adrenal insufficiency due to shifts of central hormonal production during the transition to extrauterine life. However, the preterm newborn is, additionally, at risk for adrenal insufficiency from adrenal immaturity and immature adrenal enzymes. The fetal adrenal gland generally does not synthesize cortisol de novo until about 30 weeks. 2 Before 30 weeks, the fetus uses progesterone from the placenta to bypass 3b-hydroxysteroid dehydrogenase, which is needed for de novo synthesis of cortisol. Preterm infants may be at risk for a prolonged period for developmental immaturity, as shown by decreased cortisol, and response to ACTH for several weeks after birth. 3 In addition to immature enzymes, the fetal hypothalamic-pituitaryadrenal axis is suppressed in early gestation. 2 There is suppression of the axis by passive transmission of maternal cortisol across the placenta. As gestation progresses, there are increasing levels of 11b-hydroxysteroid dehydrogenase 2, which metabolizes maternal cortisol so that there is decreasing exposure of the fetus to cortisol, thereby releasing the fetal axis from suppression by maternal cortisol.
We certainly appreciate Dr Manzar's interest in our manuscript.
